MedTrace Logo

The Texas Interprofessional Pharmacogenomics (IPGx)

NCT06219720 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-09-12

No results posted yet for this study

Summary

The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.

Conditions

  • Adverse Drug Reaction

Sponsors & Collaborators

  • InnovativeGx

    collaborator UNKNOWN

  • Texas A&M Health Family Care Clinic

    collaborator UNKNOWN

  • iC42 Clinical Research and Development

    collaborator UNKNOWN

  • Goldblatt systems

    collaborator UNKNOWN

  • Texas A&M University

    lead OTHER

Principal Investigators

  • Kenneth S Ramos, MD · Texas A&M IBT

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2026-11-30
Completion
2027-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06219720 on ClinicalTrials.gov